CN113816906A - 一种新型氮杂环庚烯的合成方法 - Google Patents
一种新型氮杂环庚烯的合成方法 Download PDFInfo
- Publication number
- CN113816906A CN113816906A CN202111223744.6A CN202111223744A CN113816906A CN 113816906 A CN113816906 A CN 113816906A CN 202111223744 A CN202111223744 A CN 202111223744A CN 113816906 A CN113816906 A CN 113816906A
- Authority
- CN
- China
- Prior art keywords
- benzylidene
- toluenesulfonylhydrazide
- methyl
- chloroform
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 238000001308 synthesis method Methods 0.000 title abstract description 4
- -1 nitrogen-containing heterocyclic compounds Chemical class 0.000 claims abstract description 47
- YIWFBNMYFYINAD-UHFFFAOYSA-N ethenylcyclopropane Chemical compound C=CC1CC1 YIWFBNMYFYINAD-UHFFFAOYSA-N 0.000 claims abstract description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 238000006352 cycloaddition reaction Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 4
- VJRITMATACIYAF-UHFFFAOYSA-N benzenesulfonohydrazide Chemical compound NNS(=O)(=O)C1=CC=CC=C1 VJRITMATACIYAF-UHFFFAOYSA-N 0.000 claims description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- UOQTXZICFVMERR-UHFFFAOYSA-N diethyl 2-ethenylcyclopropane-1,1-dicarboxylate Chemical group CCOC(=O)C1(C(=O)OCC)CC1C=C UOQTXZICFVMERR-UHFFFAOYSA-N 0.000 claims description 4
- VVFJOLBUTYLQTD-UHFFFAOYSA-N dipropan-2-yl 2-ethenylcyclopropane-1,1-dicarboxylate Chemical compound CC(C)OC(=O)C1(C(=O)OC(C)C)CC1C=C VVFJOLBUTYLQTD-UHFFFAOYSA-N 0.000 claims description 4
- 238000007142 ring opening reaction Methods 0.000 claims description 3
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- WNHPMKYMPWMAIT-UHFFFAOYSA-N 3,4,5,6-tetrahydro-2h-azepine Chemical compound C1CCC=NCC1 WNHPMKYMPWMAIT-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052786 argon Inorganic materials 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WTAPZWXVSZMMDG-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WTAPZWXVSZMMDG-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001942 cyclopropanes Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000032826 Ring chromosome 3 syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010958 [3+2] cycloaddition reaction Methods 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002546 isoxazolidines Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical class C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Abstract
高度官能化的含氮杂环化合物在天然产物、生物活性分子和手性药物分子广泛存在。然而，获得这些产品的传统方法存在条件苛刻和底物范围有限等缺点，阻碍了其潜在适用性的实现。本专利开发了一种氮杂环庚烯的高效简便的合成方法。在氩气保护条件下，以四氢呋喃为溶剂，乙烯基环丙烷与对甲苯磺酰腙进行[5+2]环加成反应，以中等至良好的收率在广泛的底物范围内合成氮杂环庚烯。该方法具有反应条件温和、操作简单、反应高效，具有极大的潜在应用价值等优点。
Description
技术领域
该专利涉及有机合成、药物合成、有机化工的研究领域，具体的方法就是乙烯基环丙烷与对甲苯磺酰腙在四氢呋喃中、在双二亚苄基丙酮钯和三苯基膦的作用下进行[5+2]环加成反应一步合成氮杂环庚烯的方法。
背景技术
高度官能化的含氮杂环是有机化学的一个重要分支。它们是天然产物、生物活性分子[1]和手性药物分子(Yu,J.；Shi,F.；Gong,L.-Z.,
Asymmetric Multicomponent Reactions for the Facile Synthesis of HighlyEnantioenriched Structurally Diverse Nitrogenous Heterocycles.Accounts ofChemical Research 2011,44(11),1156-1171)的重要骨架结构。然而，获得这些产品的传统方法存在条件苛刻和底物范围有限等缺点，阻碍了其潜在适用性的实现。因此，开发有效的方法来合成这些骨架结构具有重要意义。乙烯基环丙烷(VCP)是各种环加成过程的优良底物，其环加成反应是构建此类化合物的最有效方法之一(Chakrabarty,S.；Chatterjee,I.；Wibbeling,B.；Daniliuc,C.G.；Studer,A.,Stereospecific Formal[3+2]DipolarCycloaddition of Cyclopropanes with Nitrosoarenes:An Approach toIsoxazolidines.Angewandte Chemie International Edition 2014,53(23),5964-5968.Cui,B.；Ren,J.；Wang,Z.,TfOH-Catalyzed Formal[3+2]Cycloaddition ofCyclopropane 1,1-Diesters with Nitriles.The Journal of Organic Chemistry2014,79(2),790-796.Ghorai,M.K.；Talukdar,R.；Tiwari,D.P.,A Route to HighlyFunctionalizedβ-Enaminoesters via a Domino Ring-Opening Cyclization/Decarboxylative Tautomerization Sequivuence of Donor–Acceptor Cyclopropaneswith Substituted Malononitriles.Organic Letters 2014,16(8),2204-2207.Rivero,A.R.；Fernández,I.；Sierra,M.
Regio-and Diastereoselective Stepwise[8+3]-Cycloaddition Reaction between Tropone Derivatives and Donor–AcceptorCyclopropanes.Organic Letters 2013,15(19),4928-4931)。过渡金属偶联反应是考虑原子经济性的新杂环合成和转化中的热门研究领域，因为它可以作为反应的起始步骤，通过构建中间体使反应条件温和。早在1987年(Burgess,K.,Regioselective andstereoselective nucleophilic addition to electrophilic vinylcyclopropanes.TheJournal of Organic Chemistry 1987,52(10),2046-2051)就发现VCP由于其特殊的三元环张力结构，在路易斯酸或过渡金属催化剂的催化下可以断裂形成两性烯丙基金属络合物中间体。以3C或5C合成子的形式参与亲电试剂、亲核试剂、二烯试剂等试剂反应生成各种结构的环状化合物。对此，我们认为碳氮双键与VCP的[5+2]环加成反应为合成含氮杂环化合物提供了一种直接有效的方法。
我们在此报告了一种高效的钯催化乙烯基环丙烷与对甲苯磺酰腙的[5+2]环加成反应，得到一种新型氮杂环庚烯。
尽我们所知，未见与本申请相同的文献报道。
发明内容
本发明提供一种新型氮杂环庚烯的合成方法。
本发明公开的氮杂环庚烯合成在一步之内完成，即在四氢呋喃溶液中，以双二亚苄基丙酮钯为催化剂，三苯基膦为配体，乙烯基环丙烷开环与对甲苯磺酰腙的[5+2]环加成反应，反应一步合完成，反应方程式如下所示。
结合下面的实施例，更详细地阐述本发明，但并不认为它们是对本发明范围的限制。
具体实施方式
实施例一
将(E)-N'-亚苄基-4-甲苯磺酰肼(1mmol，1.0equiv)，双(二亚苄基丙酮)钯(0.05mmol，0.05equiv)和三苯基膦(0.2mmol，0.2equiv)添加到烘箱干燥的25mL试管中，该试管带有标准研磨接头，并配有搅拌子。用橡皮塞和胶带密封试管后，用真空泵抽空试管内的空气，然后注入氩气(重复3次)。然后将2-乙烯基环丙烷-1,1-二羧酸二乙酯(1mmol，1equiv)溶入THF(5mL)中，再用针筒注射进试管中。在室温下高速搅拌反应。以TCL检测，待反应完全，通过加入饱和NaCl溶液(10mL)淬灭反应混合物。反应混合物用乙酸乙酯(15mL×3)萃取。合并的有机相用MgSO4干燥，过滤并在旋转蒸发器上减压浓缩。所得残余物通过柱层析纯化，用石油醚/EA＝10:1洗脱，得到1-((4-甲基苯基)磺酰氨基)-2-苯基-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，为无色胶状固体，产率为82.62％。
产物1-((4-甲基苯基)磺酰氨基)-2-苯基-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯的结构表征数据如下：
1H NMR(400MHz,Chloroform-d)δ7.80(d,J＝8.2Hz,2H),7.70(s,1H),7.62(dd,J＝6.6,3.0Hz,2H),7.43–7.25(m,5H),5.73–5.48(m,2H),4.28(d,J＝5.0Hz,2H),4.23–4.02(m,4H),3.33(t,J＝7.4Hz,1H),2.59(t,J＝7.2Hz,2H),2.40(s,3H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.71,146.05,144.08,134.74,134.15,130.10,129.77,129.55,128.63,128.23,127.44,126.41,61.51,51.59,51.57,49.25,31.30,29.72,14.08,14.03.
HRMS(ESI)m/z[M+H]+Calcd for C25H31N2O6S+487.1897,found 487.1892.
HRMS(ESI)m/z[M+Na]+Calcd for C25H30N2NaO6S+509.1717,found 509.1711.
实施例二
(E)-N'-(4-溴代苯亚甲基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅黄色蜡状固体2-(4-溴苯基)-1-((4-甲基苯基)磺酰氨基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为64.68％。
1H NMR(400MHz,Chloroform-d)δ7.79(d,J＝8.0Hz,2H),7.60(s,1H),7.49(s,4H),7.30(d,J＝8.0Hz,2H),5.65(dt,J＝14.3,6.8Hz,1H),5.52(dt,J＝15.5,5.1Hz,1H),4.29(d,J＝5.0Hz,2H),4.12(p,J＝7.2Hz,4H),3.33(t,J＝7.4Hz,1H),2.59(t,J＝7.2Hz,2H),2.41(s,3H),1.21(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.63,144.20,143.39,134.78,133.22,131.79,129.85,129.60,128.74,128.11,126.17,124.08,61.56,61.47,61.38,51.53,48.98,31.26,14.09,14.04HRMS(ESI)m/z[M+H]+Calcd for C25H30BrN2O6S+565.1002,found565.0988.HRMS(ESI)m/z[M+Na]+Calcd for C25H29BrN2NaO6S+587.0822,found 587.0810
实施例三
(E)-N'-(4-乙炔基亚苄基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅棕色胶状固体2-(4-乙炔基苯基)-1-((4-甲基苯基)磺酰氨基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为37.06％。
1H NMR(400MHz,Chloroform-d)δ7.80(d,J＝8.1Hz,2H),7.65–7.52(m,3H),7.47(d,J＝8.0Hz,2H),7.30(d,J＝8.1Hz,2H),5.71–5.60(m,1H),5.52(dt,J＝15.6,5.0Hz,1H),4.32(d,J＝4.9Hz,2H),4.22–4.01(m,4H),3.34(t,J＝7.4Hz,1H),3.18(s,1H),2.59(t,J＝7.2Hz,2H),2.41(d,J＝15.7Hz,3H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.68,144.21,143.53,134.80,134.54,132.36,129.85,129.60,128.15,127.14,123.49,83.33,78.93,78.91,61.53,51.56,51.54,48.98,31.27,14.08,14.04.
HRMS(ESI)m/z[M+H]+Calcd for C27H31N2O6S+511.1897,found 511.1886
HRMS(ESI)m/z[M+Na]+Calcd for C27H30N2NaO6S+533.1717,found 533.1703
实施例四
(E)-N'-(4-乙炔基亚苄基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到黄色胶状固体1-((4-甲基苯基)磺酰氨基)-2-(4-硝基苯基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为26.72％
1H NMR(400MHz,Chloroform-d)δ8.25–8.17(m,2H),7.87–7.74(m,4H),7.61(s,1H),7.38–7.27(m,2H),5.69(dtt,J＝15.5,6.9,1.6Hz,1H),5.53(dtt,J＝15.3,5.1,1.3Hz,1H),4.42(dd,J＝5.2,1.6Hz,2H),4.19–4.05(m,4H),3.35(t,J＝7.3Hz,1H),2.65–2.58(m,2H),2.42(s,3H),1.21(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.62,148.13,144.52,140.35,139.47,134.84,130.12,129.73,128.05,127.67,125.66,123.91,61.52,51.50,48.59,31.20,21.61,14.04.
HRMS(ESI)m/z[M+H]+Calcd for C25H30N3O8S+532.1748,found 532.1729
HRMS(ESI)m/z[M+Na]+Calcd for C25H29N3NaO8S+554.1568,found 554.1540
实施例五
(E)-4-甲基-N'-(4-(三氟甲基)亚苄基)苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到黄色蜡状固体1-((4-甲基苯基)磺酰氨基)-2-(4-(三氟甲基)苯基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为79.64％
1H NMR(400MHz,Chloroform-d)δ7.81(d,J＝8.1Hz,2H),7.73(d,J＝8.1Hz,2H),7.61(d,J＝7.9Hz,3H),7.31(d,J＝8.0Hz,2H),5.74–5.60(m,1H),5.53(dt,J＝15.7,5.0Hz,1H),4.37(d,J＝4.9Hz,2H),4.11(p,J＝7.3Hz,4H),3.34(t,J＝7.4Hz,1H),2.60(t,J＝7.2Hz,2H),2.41(s,3H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.64,144.34,141.61,137.66,134.86,129.96,129.65,128.09,127.39,125.90,125.55,125.51,61.58,61.49,61.40,51.54,51.52,48.69,31.24,14.04,13.99.
HRMS(ESI)m/z[M+Na]+Calcd for C26H29F3N2NaO6S+577.1591,found 577.1580.
实施例六
(E)-4-甲基-N'-(4-((三氟甲基)硫代)亚苄基)苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅黄色蜡状固体1-((4-甲基苯基)磺酰氨基)-2-(4-((三氟甲基)硫代)苯基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为75.27％。
1H NMR(400MHz,Chloroform-d)δ7.81(d,J＝8.0Hz,2H),7.71–7.57(m,5H),7.32(d,J＝8.0Hz,2H),5.66(dt,J＝14.4,6.9Hz,1H),5.52(dt,J＝15.5,5.0Hz,1H),4.36(d,J＝4.9Hz,2H),4.21–4.01(m,4H),3.34(t,J＝7.4Hz,1H),2.60(t,J＝7.2Hz,2H),2.41(s,3H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.64,144.33,141.73,136.74,136.34,134.88,129.92,129.66,128.09,128.01,125.86,61.48,61.39,51.53,51.51,48.66,31.23,21.61,14.02.
HRMS(ESI)m/z[M+H]+Calcd for C26H30F3N2O6S2 +587.1492,found 587.1481
HRMS(ESI)m/z[M+Na]+Calcd for C26H30F3N2NaO6S2 +2 609.1311,found 609.1299
实施例七
(E)-4-甲基-N'-(4-(甲硫基)亚苄基)苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅白色胶状固体1-((4-甲基苯基)磺酰氨基)-2-(4-(甲硫基)苯基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为61.17％
1H NMR(400MHz,Chloroform-d)δ7.78(d,J＝8.3Hz,2H),7.69(s,1H),7.54(d,J＝8.2Hz,2H),7.25(dd,J＝32.5,8.1Hz,4H),5.65(dt,J＝14.2,6.8Hz,1H),5.52(dt,J＝15.6,5.2Hz,1H),4.23(d,J＝5.1Hz,2H),4.12(p,J＝7.3Hz,4H),3.33(t,J＝7.4Hz,1H),2.58(t,J＝7.2Hz,2H),2.50(s,3H),2.41(s,3H),1.21(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.68,146.25,144.07,141.50,134.64,130.75,129.77,129.53,128.20,127.77,126.50,125.83,125.80,61.56,61.48,61.39,51.57,49.44,31.29,15.28,15.20,14.09,14.03.
HRMS(ESI)m/z[M+H]+Calcd for C26H33N2O6S2 +533.1775,found 533.1767HRMS(ESI)m/z[M+Na]+Calcd for C24H32N2NaO6S2 +555.1594,found 555.1591
实施例八
(E)-4-甲基-N'-(3,4,5-三甲氧基亚苄基)苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅黄色胶状固体1-((4-甲基苯基)磺酰氨基)-2-(3,4,5-三甲氧基苯基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为71.52％。
1H NMR(400MHz,Chloroform-d)δ7.87–7.74(m,2H),7.66(s,1H),7.29(d,J＝8.1Hz,2H),6.89(s,2H),5.75–5.62(m,1H),5.61–5.48(m,1H),4.31–4.20(m,2H),4.19–4.05(m,4H),3.90(s,6H),3.87(s,3H),3.35(t,J＝7.4Hz,1H),2.67–2.55(m,2H),2.41(s,3H),1.21(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.64,153.32,146.24,144.14,139.76,134.62,129.71,129.64,129.45,128.25,126.56,104.53,104.46,61.44,61.35,56.14,56.05,51.57,49.46,21.59,14.04,14.00,13.96.
HRMS(ESI)m/z[M+H]+Calcd for C28H37N2O9S+577.2214,found 577.2222.
HRMS(ESI)m/z[M+Na]+Calcd for C28H36N2NaO9S+599.2034,found 599.2041
实施例九
(E)-4-甲基-N'-(4-(三氟甲氧基)亚苄基)苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅黄色蜡状固体1-((4-甲基苯基)磺酰氨基)-2-(4-(三氟甲氧基)苯基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为67.73％。
1H NMR(400MHz,Chloroform-d)δ7.80(d,J＝8.0Hz,2H),7.73–7.62(m,3H),7.31(d,J＝8.0Hz,2H),7.21(d,J＝8.3Hz,2H),5.66(dt,J＝14.4,6.9Hz,1H),5.52(dt,J＝15.6,5.0Hz,1H),4.31(d,J＝4.9Hz,2H),4.11(p,J＝7.5Hz,4H),3.34(t,J＝7.4Hz,1H),2.59(t,J＝7.2Hz,2H),2.41(s,3H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.66,144.23,143.15,134.77,132.92,129.86,129.61,128.75,128.13,126.15,120.97,61.48,61.40,51.55,51.54,49.01,31.25,21.61,14.03,13.99.
HRMS(ESI)m/z[M+H]+Calcd for C26H30F3N2O7S+571.1720,found 571.1723.
HRMS(ESI)m/z[M+Na]+Calcd for C26H29F3N2NaO7S+593.1540,found 593.1542
实施例十
(E)-N'-(4-甲氧基亚苄基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅白色胶状固体2-(4-甲氧基苯基)-1-((4-甲基苯基)磺酰氨基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为58.77％。
1H NMR(400MHz,Chloroform-d)δ7.87–7.72(m,3H),7.65–7.54(m,2H),7.30(d,J＝8.0Hz,2H),6.95–6.84(m,2H),5.64(dt,J＝15.4,6.8Hz,1H),5.53(dt,J＝15.5,5.2Hz,1H),4.26–4.07(m,6H),3.83(s,3H),3.33(t,J＝7.4Hz,1H),2.58(t,J＝7.1Hz,2H),2.41(s,3H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.64,161.38,148.58,143.95,134.49,129.74,129.70,129.46,129.13,128.24,126.77,114.07,114.01,61.49,61.39,61.29,55.35,55.27,51.53,49.88,49.80,31.28,29.66,21.54,21.47,14.04,13.98.
HRMS(ESI)m/z[M+H]+Calcd for C26H33N2O7S+517.2003,found 517.1988
HRMS(ESI)m/z[M+Na]+Calcd for C26H32N2NaO7S+539.1822,found 539.1808.
实施例十一
(E)-N'-(4-羟基亚苄基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到黄色胶状固体2-(4-羟基苯基)-1-((4-甲基苯基)磺酰氨基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为74.15％。
1H NMR(400MHz,Chloroform-d)δ7.81–7.71(m,3H),7.53–7.45(m,2H),7.30(d,J＝8.1Hz,2H),6.90–6.79(m,2H),5.71–5.58(m,1H),5.52(dt,J＝15.5,5.1Hz,1H),4.24–4.04(m,6H),3.34(t,J＝7.5Hz,1H),2.64–2.54(m,2H),2.06(s,1H),1.26–1.15(m,6H).
13C NMR(101MHz,Chloroform-d)δ168.92,158.61,150.06,144.14,134.14,129.76,129.58,129.54,129.46,128.30,128.26,126.81,126.11,115.75,61.64,60.63,51.61,50.12,31.29,29.69,21.58,21.09,14.17,14.05,14.01.
HRMS(ESI)m/z[M+Na]+Calcd for C25H30N2NaO7S+525.1666,found 525.1648.
实施例十二
(E)-N'-(2-羟基亚苄基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅黄色胶状固体2-(2-羟基苯基)-1-((4-甲基苯基)磺酰胺基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为81.82％。
1H NMR(400MHz,Chloroform-d)δ10.68(s,1H),8.05(s,1H),7.75–7.67(m,2H),7.38–7.23(m,4H),7.02–6.85(m,2H),5.66(dtt,J＝15.1,6.8,1.5Hz,1H),5.60–5.46(m,1H),4.22–4.02(m,6H),3.33(t,J＝7.4Hz,1H),2.58(td,J＝7.2,1.4Hz,2H),2.42(d,J＝20.9Hz,3H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.62,158.50,154.99,144.78,133.26,132.23,131.83,130.82,129.93,128.12,125.98,119.44,117.40,117.07,61.49,51.45,50.38,31.23,21.61,14.02.
HRMS(ESI)m/z[M+Na]+Calcd for C25H30N2NaO7S+525.1666,found 525.1650.
实施例十三
(E)-N'-(4-(二甲氨基)亚苄基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到黄色胶状固体2-(4-(二甲氨基)苯基)-1-((4-甲基苯基)磺酰氨基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为16.40％。
1H NMR(400MHz,Chloroform-d)δ8.02(s,1H),7.74(d,J＝8.0Hz,2H),7.55(d,J＝8.5Hz,2H),7.30(d,J＝8.0Hz,3H),6.67(d,J＝8.5Hz,2H),5.53–5.37(m,2H),4.26–4.10(m,6H),3.37(t,J＝7.5Hz,1H),3.02(s,6H),2.65(dd,J＝7.4,5.3Hz,2H),2.42(s,3H),1.25(t,J＝7.2Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.86,156.28,152.15,143.82,133.89,129.57,129.43,128.57,127.28,121.49,111.61,61.57,51.45,51.42,46.98,40.22,29.72,26.92,14.11.
HRMS(ESI)m/z[M+H]+Calcd for C27H36N3O6S+530.2319,found 530.2302
HRMS(ESI)m/z[M+Na]+Calcd for C27H35N3NaO6S+552.2139,found 552.2124.
实施例十四
(E)-N'-(4-(苄氧基)亚苄基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅黄色胶状固体2-(4-(苄氧基)苯基)-1-((4-甲基苯基)磺酰氨基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为66.88％。
1H NMR(400MHz,Chloroform-d)δ7.82–7.73(m,3H),7.61–7.55(m,2H),7.45–7.25(m,7H),7.01–6.92(m,2H),5.63(dt,J＝15.3,6.7Hz,1H),5.52(dt,J＝15.5,5.2Hz,1H),5.09(s,2H),4.24–4.03(m,6H),3.32(t,J＝7.5Hz,1H),2.58(t,J＝7.2Hz,2H),2.41(s,3H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.72,160.56,148.58,144.02,136.58,134.52,129.77,129.53,129.21,128.67,128.30,128.14,127.49,127.07,126.78,115.05,115.00,70.05,61.58,61.49,61.39,51.61,51.59,49.96,31.34,14.12.
HRMS(ESI)m/z[M+H]+Calcd for C 32H 37N 2O 7S+593.2316,found 593.2296.
HRMS(ESI)m/z[M+Na]+Calcd for C 32H 36N 2Na O 7S+615.2135,found 615.2114.
实施例十五
(E)-N'-(4-(叔丁基)亚苄基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅黄色蜡状固体2-(4-(叔丁基)苯基)-1-((4-甲基苯基)磺酰氨基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为60.38％。
1H NMR(400MHz,Chloroform-d)δ7.83–7.72(m,3H),7.61–7.53(m,2H),7.43–7.36(m,2H),7.29(d,J＝8.0Hz,2H),5.70–5.58(m,1H),5.58–5.48(m,1H),4.31–4.19(m,2H),4.11(qq,J＝10.8,7.1Hz,4H),3.32(t,J＝7.5Hz,1H),2.64–2.52(m,2H),2.40(s,3H),1.32(s,9H),1.20(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.71,153.64,147.48,143.98,134.65,131.37,129.75,129.50,128.28,127.35,126.50,125.59,61.48,51.60,49.51,34.89,31.24,31.19,14.03.
HRMS(ESI)m/z[M+H]+Calcd for C29H39N2O6S+543.2523,found 543.2505.
HRMS(ESI)m/z[M+Na]+Calcd for C29H38N2NaO6S+565.2343,found 565.2323.
实施例十六
4-甲基-N'-((E)-4-((E)-苯乙烯基)亚苄基)苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅黄色胶状固体二乙基(E)-1-((4-甲基苯基)磺酰胺基)-2-苯乙烯基-1,2,4,7-四氢-3H-氮杂环-3,3-二羧酸酯，产率为90.38％。
1H NMR(400MHz,Chloroform-d)δ7.81–7.73(m,2H),7.59(dd,J＝5.5,3.0Hz,1H),7.49–7.40(m,2H),7.40–7.25(m,5H),6.92–6.84(m,2H),5.64(dtt,J＝15.1,6.8,1.4Hz,1H),5.59–5.45(m,1H),4.24–4.07(m,6H),3.35(t,J＝7.4Hz,1H),2.65–2.55(m,2H),2.41(s,3H),1.22(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.69,149.23,144.08,139.89,135.89,134.60,129.86,129.57,128.99,128.83,128.11,127.02,126.49,125.36,61.51,51.56,49.54,31.29,21.59,14.07.HRMS(ESI)m/z[M+Na]+Calcd for C27H32N2NaO6S+535.1873,found 535.1848.
实施例十七
(E)-N'-(呋喃-2-基亚甲基)-4-甲苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到深棕色胶状固体2-(呋喃-2-基)-1-((4-甲基苯基)磺酰氨基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为79.01％。
1H NMR(400MHz,Chloroform-d)δ7.79–7.70(m,3H),7.49(dd,J＝1.9,0.8Hz,1H),7.30(d,J＝8.1Hz,2H),6.74(dd,J＝3.4,0.8Hz,1H),6.46(dd,J＝3.4,1.8Hz,1H),5.63(dtt,J＝15.1,6.8,1.4Hz,1H),5.58–5.46(m,1H),4.22–4.06(m,6H),3.33(t,J＝7.5Hz,1H),2.64–2.54(m,2H),2.41(s,3H),1.22(t,J＝7.1Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.68,149.43,144.59,144.14,139.29,134.21,130.03,129.56,128.28,126.37,113.59,111.85,61.47,51.54,50.18,31.29,21.58,14.03.
HRMS(ESI)m/z[M+Na]+Calcd for C23H28N2NaO7S+499.1509,found 499.1489.
实施例十八
(Z)-4-甲基-N'-(2,2,2-三氟-1-苯基亚乙基)苯磺酰肼代替实施例一中的(E)-N'-亚苄基-4-甲苯磺酰肼，得到浅白色胶状固体1-((4-甲基苯基)磺酰氨基)-2-苯基-2-(三氟甲基)-1,2,4,7-四氢-3H-氮杂-3,3-二羧酸二乙酯，产率为59.09％。
1H NMR(400MHz,Chloroform-d)δ7.90–7.80(m,2H),7.53–7.40(m,5H),7.36(d,J＝8.0Hz,2H),4.98(dt,J＝15.4,6.8Hz,1H),4.80–4.66(m,1H),4.27–4.05(m,4H),3.84–3.72(m,2H),3.13(t,J＝7.5Hz,1H),2.47(s,3H),2.41–2.28(m,2H),1.24(t,J＝7.2Hz,6H).
13C NMR(101MHz,Chloroform-d)δ168.55,144.87,133.11,131.69,131.09,129.54,129.44,129.27,128.77,128.63,124.48,61.53,52.35,51.26,31.05,14.07.
HRMS(ESI)m/z[M+Na]+C26H29F3N2NaO6S+577.1591,found 577.1587.
实施例十九
2-乙烯基环丙烷-1,1-二羧酸二异丙酯代替实施例一中的2-乙烯基环丙烷-1,1-二羧酸二乙酯，得到浅黄色蜡状固体二异丙基1-((4-甲基苯基)磺胺基)-2-苯基-1,2,4,7-四氢-3H-氮杂环丙烷-3,3-二甲酸酯，产率为40.58％。
1H NMR(400MHz,Chloroform-d)δ7.86–7.78(m,2H),7.71(s,1H),7.68–7.59(m,2H),7.36(qd,J＝3.7,1.6Hz,3H),7.33–7.26(m,2H),5.66(dtt,J＝15.2,6.7,1.5Hz,1H),5.58–5.47(m,1H),4.98(hept,J＝6.3Hz,2H),4.28(dd,J＝5.2,1.6Hz,2H),3.27(t,J＝7.5Hz,1H),2.63–2.53(m,2H),2.44(s,3H),1.18(dd,J＝6.3,1.1Hz,12H).
13C NMR(101MHz,Chloroform-d)δ168.25,145.91,144.05,134.79,134.17,130.07,129.93,129.55,129.52,128.62,128.23,127.45,126.22,69.05,68.96,51.89,49.26,31.23,21.67,21.55.
HRMS(ESI)m/z[M+H]+Calcd for C27H35N2O6S+515.2210,found 515.2225
HRMS(ESI)m/z[M+Na]+Calcd for C27H34N2NaO6S+537.2030,found 537.2044.
实施例二十
2-乙烯基环丙烷-1,1-二羧酸二异丙酯代替实施例一中的2-乙烯基环丙烷-1,1-二羧酸二乙酯，得到浅黄色胶状固体二苄基1-((4-甲基苯基)磺酰胺基)-2-苯基-1,2,4,7-四氢-3H-氮杂环丙烷-3,3-二甲酸酯，产率为55.92％。
1H NMR(400MHz,Chloroform-d)δ7.83–7.76(m,2H),7.68–7.58(m,3H),7.36–7.31(m,3H),7.31–7.25(m,8H),7.22(dd,J＝6.8,3.0Hz,4H),5.60(dtt,J＝15.5,7.0,1.6Hz,1H),5.49–5.38(m,1H),5.13–4.98(m,4H),4.25–4.14(m,2H),3.44(t,J＝7.4Hz,1H),2.67–2.54(m,2H),2.37(s,3H).
13C NMR(101MHz,Chloroform-d)δ168.38,146.11,144.11,135.28,134.79,134.19,130.14,129.59,128.69,128.64,128.62,128.60,128.46,128.36,128.32,128.30,128.26,127.50,126.68,67.35,67.24,67.13,51.60,51.54,49.21,31.44,31.32.
HRMS(ESI)m/z[M+H]+Calcd for C35H35N2O6S+611.2210,found 611.2227
HRMS(ESI)m/z[M+Na]+Calcd for C35H34N2NaO6S+633.2030,found 633.2044。
Claims (2)
1.一种新型氮杂环庚烯的合成方法，其特征在于：在四氢呋喃溶液中，以双(二亚苄基丙酮)钯和三苯基膦为催化剂，乙烯基环丙烷在钯催化剂作用下开环与对甲苯磺酰腙进行[5+2]环加成反应；所述的对甲苯磺酰腙为(E)-N'-亚苄基-4-甲苯磺酰肼、(E)-N'-(4-溴代苯亚甲基)-4-甲苯磺酰肼、(E)-N'-(4-乙炔基亚苄基)-4-甲苯磺酰肼、(E)-N'-(4-乙炔基亚苄基)-4-甲苯磺酰肼、(E)-4-甲基-N'-(4-(三氟甲基)亚苄基)苯磺酰肼、(E)-4-甲基-N'-(4-((三氟甲基)硫代)亚苄基)苯磺酰肼、(E)-4-甲基-N'-(4-(甲硫基)亚苄基)苯磺酰肼、(E)-4-甲基-N'-(3,4,5-三甲氧基亚苄基)苯磺酰肼、(E)-4-甲基-N'-(4-(三氟甲氧基)亚苄基)苯磺酰肼、(E)-N'-(4-甲氧基亚苄基)-4-甲苯磺酰肼、(E)-N'-(4-羟基亚苄基)-4-甲苯磺酰肼、(E)-N'-(2-羟基亚苄基)-4-甲苯磺酰肼、(E)-N'-(4-(二甲氨基)亚苄基)-4-甲苯磺酰肼、(E)-N'-(4-(苄氧基)亚苄基)-4-甲苯磺酰肼、(E)-N'-(4-(叔丁基)亚苄基)-4-甲苯磺酰肼、4-甲基-N'-((E)-4-((E)-苯乙烯基)亚苄基)苯磺酰肼、(E)-N'-(呋喃-2-基亚甲基)-4-甲苯磺酰肼、(Z)-4-甲基-N'-(2,2,2-三氟-1-苯基亚乙基)苯磺酰肼；所述的乙烯基环丙烷为2-乙烯基环丙烷-1,1-二羧酸二乙酯、2-乙烯基环丙烷-1,1-二羧酸二异丙酯、2-乙烯基环丙烷-1,1-二羧酸二异丙酯。
2.权利要求1所述的一种新型氮杂环庚烯的合成方法，其特征在于所述的乙烯基环丙烷和对甲苯磺酰腙的用量比是1:1，催化剂双(二亚苄基丙酮)的用量0.05当量，配体三苯基膦的用量是0.2当量，反应温度为室温，反应时间0.5小时。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111223744.6A CN113816906A (zh) | 2021-10-20 | 2021-10-20 | 一种新型氮杂环庚烯的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111223744.6A CN113816906A (zh) | 2021-10-20 | 2021-10-20 | 一种新型氮杂环庚烯的合成方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113816906A true CN113816906A (zh) | 2021-12-21 |
Family
ID=78920599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111223744.6A Pending CN113816906A (zh) | 2021-10-20 | 2021-10-20 | 一种新型氮杂环庚烯的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113816906A (zh) |
-
2021
- 2021-10-20 CN CN202111223744.6A patent/CN113816906A/zh active Pending
Non-Patent Citations (1)
| Title |
|---|
| 陈渊，等: "对甲苯磺酰腙与乙烯基环丙烷的加成反应" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Nickel-catalyzed C–H direct amination of benzoxazoles with secondary Amines | |
| Ying et al. | Green and efficient Knoevenagel condensation catalysed by a DBU based ionic liquid in water | |
| Han et al. | Chiral N‐phosphonyl imine chemistry: asymmetric additions of ester enolates for the synthesis of β‐amino acids | |
| CN113816906A (zh) | 一种新型氮杂环庚烯的合成方法 | |
| Pan et al. | Diastereoselective Baylis–Hillman reaction using N-glyoxyloyl camphorpyrazolidinone as an electrophile: synthesis of optically pure 2-hydroxy-3-methylene succinic acid derivative | |
| Jia et al. | Mechanosynthesis of γ-nitro dicarbonyl compounds via CaCl2-catalyzed Michael addition | |
| JP3999028B2 (ja) | 光学活性２−アシル化１，２−ジオール化合物誘導体の製造方法 | |
| KR100554085B1 (ko) | 광학적으로 활성인 형태의 아지리딘-2-카르복실산 유도체 및 그의 제조 방법 | |
| US8859812B2 (en) | Compound reagents and method for synthesizing enantiomerically enriched amino acids | |
| JP3855295B2 (ja) | ビスオキサゾリン類の製造方法 | |
| JP5408662B2 (ja) | ジスルホン酸化合物の製法、不斉マンニッヒ触媒、β−アミノカルボニル誘導体の製法及び新規なジスルホン酸塩 | |
| Bongini et al. | Synthesis of perhydroxazin-4-ones. Competitive Mukaiyama versus hetero Diels–Alder reaction in the cycloaddition of 2-aza-3-trimethylsilyloxy-1, 3-butadiene and aldehydes | |
| JP2023155765A (ja) | アミド化合物の製造方法 | |
| JPS6160822B2 (zh) | ||
| JP2005089429A (ja) | 二つのエキソメチレンを有する８員環式化合物およびその製造方法 | |
| JPH03261741A (ja) | ４―フェニル―３―ブテン―２―オンの製造法 | |
| KR101677599B1 (ko) | 신규한 피라진 유도체 및 이의 제조방법 | |
| AU2005273649B2 (en) | Enantioselective synthesis of 13-oxotricyclo[8.2.1.0 3,8]trideca-3(8),4,6-triene-5-carboxylates | |
| SU999490A1 (ru) | Способ получени алкил(фенил)сульфонилацетонитрилов | |
| JP2015136665A (ja) | 新規ビスイミダゾリン触媒およびこれを用いる水中での光学活性プロパルギルアミンの製造方法 | |
| JP5107286B2 (ja) | ホスホニルイミデートを求核剤とする方法 | |
| EP2152680B1 (fr) | Procede de preparation de n-carboxyanhydride enantiomeriquement enrichi | |
| KR100441137B1 (ko) | 키랄 2,2-디메틸시클로프로판카르복실의 유도체의 제조방법 | |
| JP5363010B2 (ja) | α―アミノジフルオロメチレン誘導体の製造方法 | |
| Xia et al. | Synthesis of a camphor-derived auxiliary and the application to the asymmetric Darzens reaction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211221 |